All In Biotech

Drug Trial Radar · NCT02063659

Telotristat Etiprate for Carcinoid Syndrome Therapy

A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome

Last checked: Nov 20, 2026Latest source record: Feb 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

76

Actual

Start

Mar 11, 2014

Primary completion

Mar 29, 2016

Study completion Mar 29, 2016

Sponsor

Lead sponsor
Lexicon PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 14, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.

Conditions

  • Carcinoid Syndrome

Interventions

  • Telotristat etiprateDrug

    Telotristat etiprate tablets

  • PlaceboDrug

    Placebo-matching telotristat etiprate tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment PeriodTime frame: First dose of study drug to within 30 days of last dose of study drug in the Double-Blind Treatment Period (Up to 17.1 Weeks)
  2. Primary: Percent Change From Baseline in Urinary 5-hydroxyindoleacetic Acid (u5-HIAA) LevelsTime frame: Baseline and 12 Weeks
  3. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Open-Label Extension PeriodTime frame: First dose of study drug to within 30 days of last dose of study drug in the Open-Label Extension Period (Up to 52.6 Weeks)

Locations

50 sites in 11 countries. Site status is shown where the registry gives one.

  • Lexicon Investigational Site

    Stanford, California

  • Lexicon Investigational Site

    Orlando, Florida

  • Lexicon Investigational Site

    Iowa City, Iowa

  • Lexicon Investigational Site

    Lexington, Kentucky

  • Lexicon Investigational Site

    Boston, Massachusetts

  • Lexicon Investigational Site

    Buffalo, New York

  • Lexicon Investigational Site

    New York, New York

  • Lexicon Investigational Site

    Philadelphia, Pennsylvania

  • Lexicon Investigational Site

    Kogara, New South Wales, Australia

  • Lexicon Investigational Site

    St Leonards, New South Wales, Australia

  • Lexicon Investigational Site

    Herston, Queensland, Australia

  • Lexicon Investigational Site

    East Melbourne, Victoria, Australia

  • Lexicon Investigational Site

    Edegem, Belgium

  • Lexicon Investigational Site

    Ghent, Belgium

  • Lexicon Investigational Site

    Yvoir, Belgium

  • Lexicon Investigational Site

    Calgary, Alberta, Canada

  • Lexicon Investigational Site

    Halifax, Nova Scotia, Canada

  • Lexicon Investigational Site

    Clichy, France

  • Lexicon Investigational Site

    Lille, France

  • Lexicon Investigational Site

    Lyon, France

  • Lexicon Investigational Site

    Marseille, France

  • Lexicon Investigational Site

    Strasbourg, France

  • Lexicon Investigational Site

    Villejuif, France

  • Lexicon Investigational Site

    Bad Berka, Germany

  • Lexicon Investigational Site

    Berlin, Germany

  • Lexicon Investigational Site

    Hamburg, Germany

  • Lexicon Investigational Site

    Heidelberg, Germany

  • Lexicon Investigational Site

    Lübeck, Germany

  • Lexicon Investigational Site

    Mainz, Germany

  • Lexicon Investigational Site

    Marburg, Germany

  • Lexicon Investigational Site

    Munich, Germany

  • Lexicon Investigational Site

    Neuss, Germany

  • Lexicon Investigational Site

    Jerusalem, Israel

  • Lexicon Investigational Site

    Noord Brahant, Netherlands

  • Lexicon Investigative Site

    Rotterdam, Netherlands

  • Lexicon Investigational Site

    Amsterdam, North Holland, Netherlands

  • Lexicon Investigational Site

    Amsterdam, North Holland, Netherlands

  • Lexicon Investigational Site

    Barcelona, Spain

  • Lexicon Investigational Site

    Barcelona, Spain

  • Lexicon Investigational Site

    Madrid, Spain

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.